drug

Bio & Pharma Celltrion unveils cancer medicine to expand new drug pipelines

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

Bio & Pharma Celltrion expands footprint in Latin America with flagship oncology drugs

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Bio & Pharma Celltrion wins Australian approval for eye, bone disease biosimilars

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Bio & Pharma Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

Bio & Pharma SillaJen: First to use lab-grown human tissue to find best cancer drug dose

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

Bio & Pharma Chong Kun Dang to build new plant for foray into biologics market

Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Bio & Pharma Lotte Biologics eyes first ADC CDMO order in 2025

SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...

IPOs Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut

SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...

Bio & Pharma SK Biopharmaceuticals, Eurofarma to set up AI epilepsy platform JV in US

South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...

Bio & Pharma Yuhan’s lung cancer drug gets OK in Europe

Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...

Bio & Pharma Boryung, Lotus Pharma signs CDMO deal on anticancer injection

South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...

Bio & Pharma SK Biopharm submits NDA of epilepsy drug to China

South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...

Bio & Pharma Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

Bio & Pharma Hanmi Pharma to move up launch of anti-obesity drug

South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...

Bio & Pharma Samsung Biologics wins $668 million CDMO deal with European pharma

Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...

Bio & Pharma Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....

Bio & Pharma Yuhan’s lung cancer drug clears FDA hurdle for global debut

A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...

Bio & Pharma IMBiologics transfers autoimmune disease drug tech to Huadong Pharma

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

Bio & Pharma Costco sells Celltrion's Yuflyma Low WAC in US

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

Bio & Pharma Celltrion's Zymfentra joins US insurance-covered drug lists

South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (inflixim...

Bio & Pharma Huonslab eyes speedy anticancer drug delivery with new patent

South Korean biotech Huons Global Co. said on Tuesday that its research and development unit Huonslab has issued a domestic patent claiming a techno...

Bio & Pharma SK Biopharm mulls acquiring firms, drug sales rights in US

SAN DIEGO, California -- South Korea’s SK Biopharmaceuticals Co. is considering acquiring firms in the US, or the sales rights to some of thei...

Bio & Pharma Handok gets Biocon's obesity drug exclusive distribution in S.Korea

South Korean pharmaceutical company Handok Inc. announced on Friday that it signed an exclusive domestic sales and distribution agreement with India...

Bio & Pharma Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

Bio & Pharma S.Korean anti-obesity drugmakers eye niche demand

The global weight management market has entered a new chapter following the arrival of blockbuster weight-loss medication Wegovy, and South Korean l...

Bio & Pharma HK inno.N to release K-CAB in MENA market

South Korean bio-health company HK inno.N announced on Tuesday that it signed a contract with Saudi Arabian local pharmaceutical company Tabuk Pharm...

Mergers & Acquisitions Blackstone signs over $1 bn deal with MBK for 1st exit in Korea

Private equity giant Blackstone Inc. is set to mark its first exit from South Korea by selling a 71.25% stake in the holding firm of Geo-Young Corp....

Bio & Pharma Samsung begins new drug development for rare diseases

Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...

Bio & Pharma Drug maker Boryung targets its highest-ever sales in 2024

Boryung Corp., formerly Boryung Pharmaceutical Co., aims to join the 1 trillion won ($748 million) sales club this year, driven by new chronic disea...